| 000 | 01883 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516122715.0 | ||
| 264 | 0 | _c20140319 | |
| 008 | 201403s 0 0 eng d | ||
| 022 | _a1699-3055 | ||
| 024 | 7 |
_a10.1007/s12094-012-0971-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPietrantonio, F | |
| 245 | 0 | 0 |
_aLack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. _h[electronic resource] |
| 260 |
_bClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico _cJul 2013 |
||
| 300 |
_a582-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCamptothecin _xadministration & dosage |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aIrinotecan |
| 650 | 0 | 4 |
_aLeucovorin _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_abcl-2-Associated X Protein _xmetabolism |
| 700 | 1 | _aBiondani, P | |
| 700 | 1 | _aMilione, M | |
| 700 | 1 | _aMelotti, F | |
| 700 | 1 | _aBertarelli, G | |
| 700 | 1 | _aPerrone, F | |
| 700 | 1 | _ade Braud, F | |
| 700 | 1 | _aMariani, L | |
| 700 | 1 | _aFanetti, G | |
| 700 | 1 | _aCortinovis, D | |
| 700 | 1 | _aDi Bartolomeo, M | |
| 773 | 0 |
_tClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico _gvol. 15 _gno. 7 _gp. 582-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s12094-012-0971-3 _zAvailable from publisher's website |
| 999 |
_c22290529 _d22290529 |
||